Site search

Clear filter
2983 results for '' found
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed with Epilepsy (NCT07238868)
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of CB03-154 in Subjects Diagnosed with Epilepsy (NCT07238868)
/
An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab [MOONSHOT] (ACTRN12625000387426)
An ALLG phase II trial of Epcoritamab consolidation in high genomic risk and MRD+ CLL patients after first-line venetoclax + obinutuzumab [MOONSHOT] (ACTRN12625000387426)
/
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial (NCT07430267)
Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial (NCT07430267)
/
Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)
Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)
/
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT06966401)
A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT06966401)
/
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT07196501)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder [MDD] (NCT07196501)
/
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE (NCT07204938)
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE (NCT07204938)
/
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (NCT06443463)
A Phase 2, Global, Multicenter, Long-term Safety Study Designed to Assess the Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (NCT06443463)
/
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 65 years with alcohol-related liver disease (NCT06613698)
/
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in pe
Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in pe
/
4 5 6 7 8